The medical device company's stock was surging Wednesday on the news.
The changes at the helm and to the board come in the wake of pressure from Broadfin Capital, which holds a significant stake in Nevro.
BMO Capital Markets analyst Joanne Wuensch upgraded Nevro from Market Perform to Outperform and increased the price target from $46 to $67.
Despite the value of Nevro's franchise, successive downward revisions and management missteps were keeping BMO on the
"While it suspended guidance, and turnarounds do take time, this is a very good step in our view," the analyst said.
Newly appointed CEO Keith Grossman, who replaced Rami Elghandour at the helm, is a medical device industry veteran, she said.
The appointment should give the company a fresh perspective and reinvigorate its growth profile in a still-strong spinal cord stimulation market, Wuensch said.
"We suspect that this assignment will mark the turnaround of the organization, but also stir the pot on how long it will stay as an independent company given his history."
The two independent directors joining the board — Elizabeth Weatherman and Kevin O'Boyle — have a long list of board positions and "long and heralded" stints in the medical device industry on their résumés, according to BMO.
The Price Action
Nevro shares were rallying 33.21 percent to $59.64 at the time of publication Wednesday.
The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company
Altimmune's Flu Shot Study: What You Need To Know
Latest Ratings for NVRO
|Mar 2019||Wells Fargo||Upgrades||Market Perform||Outperform|
|Mar 2019||BMO Capital||Upgrades||Market Perform||Outperform|
|Mar 2019||Bank of America||Upgrades||Neutral||Buy|
View More Analyst Ratings for NVRO
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company
- The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
- The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.